CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

AT-527Wiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (2)

Name (Synonyms) Correlation
drug76 Any drug used to treat Covid-19 Wiki 1.00
drug850 Placebo Wiki 0.09

Correlated MeSH Terms (4)

Name (Synonyms) Correlation
D007049 Iatrogenic Disease NIH 1.00
D058186 Acute Kidney Injury NIH 0.41
D012128 Respiratory Distress Syndrome, Adult NIH 0.11
D018352 Coronavirus Infections NIH 0.05

Correlated HPO Terms (1)

Name (Synonyms) Correlation
HP:0001919 Acute kidney injury HPO 0.41

There is one clinical trial.

Clinical Trials

1 A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of AT-527 in Subjects With Moderate COVID-19

The objectives of this study are to evaluate the safety, tolerability and efficacy of AT-527 in older subjects (ages 45-80 years) with moderate COVID-19 and risk factors for poor outcomes (such as obesity (BMI>30), hypertension, diabetes or asthma). Eligible subjects will be randomized to blinded AT-527 (nucleotide analog) tablets or matching placebo tablets to be administered orally for 10 days. Local supportive standard of care (SOC) will be allowed for all subjects. Efficacy and safety observations will be compared for treatment with active AT-527 tablets + SOC vs. placebo tablets + SOC.

NCT04396106 COVID-19 Drug: AT-527 Other: Placebo

Primary Outcomes

Description: Respiratory failure defined as requirement for intubated mechanical ventilation.

Measure: Proportions (active vs. placebo) of subjects who progress to respiratory failure

Time: Day 14 and Follow-up Day 14

Measure: Proportions (active vs. placebo) of subjects experiencing treatment-emergent adverse events

Time: Day 14 and Follow-up Day 14

Secondary Outcomes

Description: Clinical recovery defined as time from start of treatment until normal body temperature and respiratory rate (<20 breaths per minute), with sufficient alleviation of other signs and symptoms to support discharge

Measure: Time to clinical recovery

Time: Day 14

No related HPO nodes (Using clinical trials)